| Literature DB >> 32576922 |
Steffen Brodt1, Georg Matziolis2, Bettina Buckwitz3, Timo Zippelius2, Patrick Strube2, Andreas Roth4.
Abstract
The present paper is concerned with the investigation of the phenomenon of long-term bone remodelling on cementless hip replacements. Changes in bone density in the periprosthetic region around the stem, measured by dual X-ray absorptiometry (DXA), were used as a measure of the osseous adaptation reaction. A postoperative follow-up of the use of four different types of prostheses of varying design after on average 13.3 (11.4-14.5) years. Specifically, the prostheses assessed in this study were the CLS/Spotorno stem with the Allofit cup by Zimmer, the Vision 2000 stem with the Duraloc cup by DePuy Synthes, the AlphaFit stem with the AlphaLock cup by Corin and the Mayo stem with the Trilogy cup by Zimmer. For the DXA measurement, the femur was divided into the zones suggested by Gruen et al. On the femur, there was a significant reduction in bone mineral density (BMD) in the proximal Region Of Interest (ROI) 1 (p = 0.003) and 7 (p < 0.001), whilst there was a significant increase in ROI 4 (p = 0.03). A greater degree of bone atrophy was seen in patients aged 60 years and older and in female patients. A remarkable finding when comparing the stems was a significantly greater reduction in BMD in ROI 6 (p = 0.003) in the case of the Vision 2000 stem and a markedly, but not statistically significantly smaller reduction in BMD in ROI 7 (p = 0.18) in the case of the short-stem Mayo-type prosthesis. The best clinical results were found with the use of the latter. The investigations provide a starting point for establishing a differential indication in the choice of prosthesis types, depending on age and sex, the use of short-stem prostheses, as well as the administration of bone-effective drugs for the prevention of stress shielding.Entities:
Mesh:
Year: 2020 PMID: 32576922 PMCID: PMC7311465 DOI: 10.1038/s41598-020-67189-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow Diagram.
Number of prostheses followed up according to type.
| Prosthesis type | Stem | CLS | Vision 2000 | AlphaFit | Mayo | Total(median) |
|---|---|---|---|---|---|---|
| Cup | Allofit | Duraloc | AlphaLock | Trilogy | ||
| Number of patients, initial population | 26 | 29 | 18 | 8 | 81 | |
| Number of patients, current | 15 | 11 | 8 | 7 | 41 | |
| male | 2 | 1 | 5 | 3 | 11 | |
| female | 13 | 10 | 3 | 4 | 30 | |
| Proportion of retraced patients in % | 57.7% | 37.9% | 44.4% | 87.5% | 50.6% | |
Figure 2CLS Spotorno stem, Vision 2000 stem, AlphaFit stem and Mayo stem (from left to right).
Characteristics of the different stem types.
| Stem | Alloy | Anchoring | shape | surface design |
|---|---|---|---|---|
| CLS Spotorno | titanium | metaphyseal | conical in frontal and lateral plane | corundum blasted |
| Vision 2000 | cobalt-chrome | meta-/diaphyseal | straight, macro-structure | proximal Porocoat®, distal polished |
| AlphaFit | titanium | meta-/diaphyseal | straight, macro-structure | proximal calcium phosphate coated, distal polished |
| Mayo | titanium | metaphyseal | short-stem, double wedge-shaped | proximal macro-structure with fibre-mesh |
Figure 3Position of the ROIs on the CLS Spotorno, Vision2000, AlphaFit and Mayo stems (from left to right).
Figure 4Change in the mean BMD on the femur at follow-up compared with the postoperative baseline value according to ROI and prosthetic stem (*denotes significant changes).
Change in BMD (±SD) on the femur in g/cm2 and in % of the baseline value (*statistically significant at p < 0.05).
| Model | ROI 1 | ROI 2 | ROI 3 | ROI 4 | ROI 5 | ROI 6 | ROI 7 |
|---|---|---|---|---|---|---|---|
| CLS | −0.032 (±0.169)−4.41% | 0.009 (±0.287) 0.76% | 0.073 (±0.161) 4.74% | 0.089 (±0.150) 5.75% | 0.087 (±0.129) 5.48% | −0.145 (±0.152)−10.97% | −0.274 (±0.264)−24.85% |
| Vision 2000 | 0.110 (±0.066)−17.12% | −0.171 (±0.183)−14.05% | 0.067 (±0.079) 5.01% | −0.044 (±0.297%)−2.91% | −0.023 (±0.325)−1.62% | − | −0.313 (±0.344)−33.04% |
| AlphaFit | −0.069 (±0.151)−10.19% | −0.034 (±0.237)−2.75% | −0.120 (±0.505)−7.47% | 0.058 (±0.121) 3.60% | −0.057 (±0.404)−3.35% | −0.037 (±0.160)−3.13% | −0.293 (±0.268)−29.76% |
| Mayo | −0.089 (±0.197) 11.62% | −0.073 (±0.192)−5.12% | −0.099 (±0.320)−5.72% | −0.044 (±0.168)−2.68% | −0.121 (±0.238)−7.19% | 0.036 (±0.159) 2.65% | −0.046 (±0.163)−5.16% |
| all groups combined | − | −0.063 (±0.237)−5.03% | 0.005 (±0.277) 0.34% | 0.025 (±0.255) 1.58% | −0.006 (±0.274)−0.35% | −0.155 (±0.225)−12.30% | − |
Global index of the WOMAC and sum of the Harris Hip Score (*statistically significant at p < 0.05).
| Score | CLS/Allofit | Vision2000/Duraloc | AlphaFit/AlphaLock | Mayo/Trilogy | total |
|---|---|---|---|---|---|
| WOMAC | 1.29 (0.66) | 1.98 (1.58) | 1.69 (0.88) | 1.44 (0.94) | |
| Mean ± SD | ±1.29 | ±1.78 | ±2.14 | ±1.54 | |
| Harris Hip Score Mittelwert (SD) Duraloc | 85 (95) | 88 (95) | 85 (86) | 91 (95) | 85,00 (91) |
| Mean ± SD | ±18.28 | ±18.63 | ±13.61 | ±8.23 | ±17.94 |
Means of the postoperative BMD in g/cm2 on the stem according to ROI and sex (*statistically significant at p < 0.05).
| Patient group | ROI 1 | ROI 2 | ROI 3 | ROI 4 | ROI 5 | ROI 6 | ROI 7 |
|---|---|---|---|---|---|---|---|
| women | 0.683 | 1.245 | 1.509 | 1.515 | 1.258 | 1.003 | |
| men | 0.728 | 1.264 | 1.573 | 1.682 | 1.280 | 1.000 |